Document is current
Any future updates will be listed below
-
Authors
Müller, Fabian https://orcid.org/0000-0001-5487-5839
Wirsching, Andreas
Hagen, Melanie
Völkl, Simon
Tur, Carlo
Raimondo, Maria Gabriella https://orcid.org/0000-0003-2020-6711
Taubmann, Jule
Bucci, Laura
Zhang, Liang
Kretschmann, Sascha https://orcid.org/0000-0001-8168-7542
Aigner, Michael
Eckstein, Markus https://orcid.org/0000-0001-5418-3349
Spörl, Silvia
Kharboutli, Soraya
Böltz, Sebastian https://orcid.org/0000-0001-5227-8707
Atzinger, Armin
Munoz, Luis
Schett, Georg https://orcid.org/0000-0001-8740-9615
Mackensen, Andreas https://orcid.org/0000-0002-0685-4483
Grieshaber-Bouyer, Ricardo https://orcid.org/0000-0002-2873-5135
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft
- License Information
-
More Information
Article History
Received: 11 January 2025
Accepted: 16 April 2025
First Online: 17 April 2025
Competing interests
: F.M. has received research funding from AstraZeneca and Kite/Gilead, was advising ArgoBio, AstraZeneca, BMS, CRISPR Therapeutics, Janssen, Kite/Gilead, Miltenyi, Novartis and Sobi, and received honoraria from Abbvie, AstraZeneca, Beigene, BMS, Janssen, Kite/Gilead, Miltenyi, Novartis, Sobi and Takeda. G.S. has received speaker honoraria from BMS, Cabaletta, Kyverna, Janssen, Miltenyi and Novartis. A.M. has received research funding from Kyverna and Miltenyi Biomedicine along with consulting fees from Biontech, BMS/Celgene, Century Therapeutics, KITE/Gilead, Miltenyi Biomedicine and Novartis. R.G.-B. has received research support from Kyverna and speaker honoraria from BMS, Kyverna and Novartis. No commercial sponsor was involved in the study design, interpretation or writing of the manuscript. The other authors declare no competing interests.
